• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Risk of major adverse cardiovascular events varies with dynamic metabolic syndrome status

byThomas SuandDeepti Shroff
December 4, 2019
in Cardiology, Chronic Disease, Endocrinology, Gastroenterology, Public Health
Reading Time: 3 mins read
Many new pediatric asthma cases attributable to obesity
Share on FacebookShare on Twitter

1. In this retrospective study involving South Koreans with no history of major adverse cardiovascular events (MACE), persons who developed metabolic syndrome (MetS) within the three-year inclusion period were at significantly increased risk of MACE versus those who remained free of the condition. Persons who had MetS at the beginning of the study and recovered before the end faced a significantly lower MACE risk compared to those who did not.

2. While MetS-developed and MetS chronic patients had similar risks for MACE, patients in the MetS-recovery group retained a higher risk than patients in the MetS-free group, underscoring the immediacy and persistence of the condition’s effects on the cardiovascular system.

Evidence Rating Level: 2 (Good)

Study Rundown: While it is well known that patients with metabolic syndrome (MetS) face an increased risk for major adverse cardiovascular events (MACE), it is unclear whether development of or recovery from MetS affects the incidence rate of MACE. Given the increasing medical burden of these concomitant illnesses, it is essential to better characterize this association. This study relied on health screening data from the National Health Insurance Service of Korea and found that MACE risk varied strongly with dynamic MetS status during the three-year inclusion period. The MetS-chronic group faced the highest risk, followed by the MetS-developed, MetS-recovery, and MetS-free groups, respectively. The components of MetS were analyzed, and hypertension was found to have the strongest association with MACE risk. These results support preventative public health policies and highlight the clinical importance of a MetS history. A major strength of this study was that it utilized comprehensive health information from an extremely large population. However, this study’s retrospective nature made it difficult to detecting confounding factors, and the short follow-up and homogenous cohort composition affected generalizability of findings.

Click here to read the study in Annals of Internal Medicine

Relevant Reading: The Global Epidemic of the Metabolic Syndrome

RELATED REPORTS

A lower threshold for referral to the emergency department for outpatient hyperkalemia may reduce mortality

Borderline-low hemoglobin levels linked to increased mortality

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

In-Depth [retrospective cohort]: In this nationwide population-based study, South Korean adults with no history of MACE were divided into four categories according to MetS status over a 3-year timeframe. Over 9.5 million persons met the inclusion criteria of identifiable MetS status at 3 or more health examinations during the inclusion period. Some exclusion criteria were transient change in MetS status, change in MetS status at the third examination, and underlying kidney function impairment. Persons were considered to have MetS if they displayed 3 or more of the following components: increased waist circumference (≥90 cm for Asian men and ≥80 cm for Asian women); elevated triglyceride level (≥50 mg/dL); reduced high-density lipoprotein cholesterol level (<40 mg/dL for men and 50 mg/dL for women); elevated blood pressure (systolic ≥130 mm Hg and/or diastolic ≥80 mm Hg); and elevated fasting glucose level (≥100 mg/dL). Of these components, development of and recovery from hypertension had the greatest impacts on MACE risk. MACE occurred most frequently in the MetS-chronic group (8.52 events per 1000 person-years) and MetS-developed group (6.05 events per 1000 person-years). The MetS-recovery group (4.55 events per 1000 person-years) and MetS-free group (1.92 events per 1000 person-years) faced the lowest risk of MACE.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiac riskhypertensionmetabolic syndromemortalityobesity
Previous Post

#VisualAbstract: Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping

Next Post

#VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

RelatedReports

Emergency

A lower threshold for referral to the emergency department for outpatient hyperkalemia may reduce mortality

September 16, 2026
Cardiology

Borderline-low hemoglobin levels linked to increased mortality

September 14, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

September 4, 2026
“Housing First” linked to housing stability for homeless youth with mental illness
Public Health

Mortality in the post-housing period is high among homeless people in Ottawa, Canada

August 31, 2026
Next Post
#VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

#VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Adalimumab aids in control of noninfectious uveitis

Optic nerve ultrasonography can be used to detect elevated intracranial pressure

#VisualAbstract: Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis

#VisualAbstract: Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Nirsevimab (Beyfortus) may reduce severe respiratory syncytial virus infections among infants
  • An artificial intelligence (AI) tool achieved high diagnostic accuracy for the identification and prediction of sepsis
  • Use of long-acting broadly neutralizing antibodies may delay human immunodeficiency virus (HIV) rebound following discontinuation of antiretroviral therapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.